Edition:
United States

Nitto Denko Corp (6988.T)

6988.T on Tokyo Stock Exchange

8,207JPY
1 Dec 2016
Change (% chg)

¥311 (+3.94%)
Prev Close
¥7,896
Open
¥8,010
Day's High
¥8,382
Day's Low
¥8,004
Volume
1,973,300
Avg. Vol
1,009,914
52-wk High
¥8,964
52-wk Low
¥5,175

Latest Key Developments (Source: Significant Developments)

Nitto Denko Avecia Inc acquires businesses of Irvine Pharmaceutical Services, Avrio Biopharmaceuticals
Tuesday, 11 Oct 2016 03:00pm EDT 

Irvine Pharmaceutical Services: Nitto Denko Avecia Inc. acquires the businesses of Irvine Pharmaceutical Services & Avrio Biopharmaceuticals .Irvine Pharmaceutical Services - Avecia will consolidate both businesses into newly established company, Nitto Avecia Pharma Services.  Full Article

Nitto Denko acquires two U.S. Biomedical companies - nikkei
Tuesday, 11 Oct 2016 01:49pm EDT 

Nikkei: Nitto Denko has acquired two U.S. Biomedical companies so it can handle all drug production steps on its own - nikkei .Nitto Denko will upgrade its synthesis plant in the U.S. State of Massachusetts by June 2017- nikkei.  Full Article

Future says lawsuit filed by NITTO DENKO
Friday, 5 Aug 2016 02:29am EDT 

Future Corp <4722.T>: Says NITTO DENKO CORPORATION <6988.T> filed lawsuit to against the judgment disclosed on June 17 regarding the co and the co's unit .Says NITTO DENKO demands court to withdraw the judgment and reject unit's appeal, as well as demands the co and unit to pay 1.46 billion yen and related interest.  Full Article

Future wins lawsuit
Wednesday, 22 Jun 2016 04:29am EDT 

Future Corp <4722.T>: Says it won a lawsuit filed by the co to against NITTO DENKO CORPORATION <6988.T> regarding contract payment . Says its unit takes the lawsuit after company split . Says NITTO DENKO was ordered to pay 1.46 billion yen and related payment to the unit .Says NITTO DENKO's countercharge was rejected by court.  Full Article

Nitto signs partnership agreement with Daiichi Sankyo
Tuesday, 10 May 2016 09:00am EDT 

Nitto Denko Corp <6988.T> : Signed a partnership agreement with Daiichi Sankyo company, ltd. . Nitto will provide exclusive rights to passport system for an undisclosed compound owned by daiichi sankyo . Financial terms were not disclosed. .Will support clinical development of candidate in united states..  Full Article

NITTO DENKO announces merger between units
Friday, 8 Apr 2016 04:30am EDT 

NITTO DENKO CORP:Says its Tokyo-based wholly owned subsidiary to merge with its two wholly owned subsidiaries located in Osaka and Ehime respectively, effective on July 1.Says Osaka-based and Ehime-based units to be dissolved after the transaction.  Full Article

R&I affirms NITTO DENKO’s rating at "AA-" and rating outlook stable
Monday, 28 Mar 2016 02:00am EDT 

NITTO DENKO CORP:Rating and Investment Information, Inc. (R&I) affirmed NITTO DENKO's rating at "AA-".Rating outlook stable.  Full Article

NITTO DENKO to issue mid-year dividend and raises year-end dividend forecast for FY 2016
Friday, 30 Oct 2015 03:00am EDT 

NITTO DENKO CORP:To issue a mid-year dividend of 70 yen per share to all the shareholders of record as of Sep. 30, for the fiscal year ending March 2016.Payment date Nov. 27.Says the dividend is above latest forecast of 65 yen per share.Says it raised the year-end dividend forecast to 70 yen per share from 65 yen per share for the fiscal year ending March 2016.  Full Article

NITTO DENKO to issue year-end dividend for FY 2015
Thursday, 30 Apr 2015 03:00am EDT 

NITTO DENKO CORP:To issue a year-end dividend of 65 yen per share, for the FY ended March 2015.Dividend issued to shareholders of record as of March 31.Dividend payment date June 22.Says the dividend amount is above the latest forecast of 55 yen per share disclosed on Oct. 31, 2014.  Full Article

R&I affirms NITTO DENKO's rating at "AA-" and stable outlook
Monday, 16 Mar 2015 02:00am EDT 

NITTO DENKO CORP:Rating and Investment Information, Inc. (R&I) affirmed NITTO DENKO's rating at "AA-".Rating outlook stable.  Full Article

Bristol-Myers' deepens focus on fibrosis with Nitto deal

Bristol-Myers Squibb Co said on Thursday it agreed to pay Japan's Nitto Denko Corp $100 million up front for the right to its early-stage drug for liver fibrosis due to fatty liver disease NASH or hepatitis C.